MERTK and breast carcinoma: Mer-targeted compounds, such as UNC2250 (54), UNC9253 (55), SA4488 (56), and UNC2025 (57), have been investigated to inhibit Mer kinase activity in different murine tumor models like melanoma, prostate, pancreatic, and breast cancer (26).